<sup>177</sup> Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

Compared with SBRT alone, the addition of <sup>177</sup>Lu-PNT2002 to SBRT significantly improved PFS in patients with orHSPC without an attendant increase in toxicity.

Authors

Institutions

Publication Details

Journal
Journal of Clinical Oncology
Published
2025-11-12
DOI
https://doi.org/10.1200/jco-25-01553
Citations
6
Primary Topic
Prostate Cancer Treatment and Research
Type
article
Field-Weighted Citation Impact
9.11
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

177 Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

Mariko Nakayama, Paul C. Boutros, Zachary Ells, Holly Wilhalme et al.
6 citations
Journal of Clinical Oncology
Prostate Cancer Treatment and Research
9.11
article

177 Lu-Prostate-Specific Membrane Antigen Neoadjuvant to Stereotactic Ablative Radiotherapy for Oligorecurrent Prostate Cancer (LUNAR): An Open-Label, Randomized, Controlled, Phase II Study

Mariko Nakayama, Paul C. Boutros, Zachary Ells, Holly Wilhalme, Vinícius Ludwig, Jérémie Calais, Johannes Czernin, Amar U. Kishan, Minsong Cao, Luca Valle, Daniel Karasik, Ting Martin, Martin Allen-Auerbach, Matthew B. Rettig, Catherine Meyer, Sophia Parmisano, Kevin Flores, Nicholas G. Nickols, T. Vincent Basehart, Joanne B. Weidhaas, Wayne Brisbane, Magnus Dahlbom, Michael L. Steinberg, Michael Lauria, Kristen M. McGreevy, Donatello Telesca, Leonard S. Marks, Javier Casillas, Carol Felix, R. Nabong
article en
6 citations

Abstract

Compared with SBRT alone, the addition of <sup>177</sup>Lu-PNT2002 to SBRT significantly improved PFS in patients with orHSPC without an attendant increase in toxicity.

Journal of Clinical OncologyVol. 43(36)
University of California, Los Angeles (US), University of Washington (US), VA West Los Angeles Medical Center (US), Statistical Research (United States) (US), University of San Francisco (US)
Openalex Percentile: Top 2%
Prostate Cancer Treatment and Research
9.11
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.